Endo takes heart at FDA panel cancellation
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals is viewing the news that theFDA says it no longer sees a need to convene an advisory committee meeting, planned for 2 December, to review an NDA for a new oral formulation tablet version of long-acting oxymorphone, designed to be crush-resistant as positive news.